This article explores the 15 cheapest stocks insiders are buying in March. Previously, we covered the 14 most expensive stocks insiders are buying in March.

After solid gains Monday, the broader market index and blue chip companies traded flat Tuesday, while the NASDAQ Composite rose 0.2%. Monday’s enthusiasm came from hopes of looser U.S. tariffs.

Investors mostly ignored the March consumer confidence data released on Tuesday, which showed a sharp decline in U.S. consumers’ short-term outlook on income, business, and job conditions, reports CNBC.

“Sentiment continues to wane among investors, consumers and businesses as economic concerns and economic policy uncertainty takes its toll,” said Bret Kenwell, U.S. investment analyst at eToro. “Until there’s more certainty on the tariff and macro front, sentiment and confidence remain vulnerable.”

As investors navigate daily market changes, uncertainty remains a persistent factor. Insider trading tends to attract attention during these periods, as purchases of company stock by executives may suggest optimism about the company’s future. However, insider selling doesn’t necessarily signal a lack of confidence—it could simply be for personal financial reasons or to diversify holdings. Many executives use pre-established plans, such as 10b5-1, to maintain transparency. While insider trading can provide useful insights, it’s important to evaluate it alongside a company’s financial stability, broader market trends, and industry dynamics.

What are some of the cheapest stocks insiders have been buying this month so far? To find out, we used Insider Monkey’s insider trading stock screener, focusing only on stocks where at least two insiders had purchased shares in March. From there, we ranked the 10 stocks with the lowest average price per share.

Our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds, focusing on insider trading and stock picks from hedge fund investor newsletters and conferences. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 373.4% since May 2014, beating its benchmark by 218 percentage points (see more details here).

With each stock, we note the average price per share of these purchases and the stock’s market capitalization. Let’s take a look at the 15 cheapest stocks insiders are buying in March.

15. Aware, Inc. (NASDAQ:AWRE)

Market Capitalization: $34.6 million

Aware provides biometric software solutions for government and commercial clients worldwide. Its products include biometric identification systems, mobile frameworks, and identity verification tools, catering to industries like law enforcement and healthcare. The Burlington, Massachusetts-based company offers its solutions through various sales channels, including direct, integrators, and resellers.

For the full year 2024, Aware disclosed revenue of $17.4 million, down from $18.2 million in 2023. Net loss improved 39% to $4.4 million, compared to $7.3 million in the previous year. Adjusted EBITDA loss improved 15% to $3.9 million compared to $4.6 million in 2023.

This month, four insiders, including the president and CEO, bought $135,463 worth of Aware shares at an average price of $1.57 per share. Year-to-date, the stock is down 14.33%, trading at $1.67 per share. Over the past 12 months, Aware shares declined 6.15%.

Analyst coverage for Aware stock is currently limited.

14. CPS Technologies Corporation (NASDAQ:CPSH)

Market Capitalization: $24.84 million

CPS Technologies Corporation provides advanced material solutions for industries like transportation, automotive, aerospace, and defense. The Norton, Massachusetts-headquartered company specializes in metal matrix composites, which are used in various applications such as electric vehicles, radar, and military armor. CPS Technologies sells its products to microelectronics systems companies and operates globally in the U.S., Europe, and Asia.

For the fourth quarter of 2024, CPS Technologies reported revenue of $5.9 million versus $6.7 million in the prior-year period. The company noted that the revenue drop reflects the previously announced fulfillment of its HybridTech Armor contract with Kinetic Protection for the U.S. Navy. Net loss was $1.0 million or $0.07 loss per diluted share, which compares to net income of $200,000 or $0.01 per diluted share in the same period of 2023.

In March, two insiders acquired approximately $42,030 worth of CPS Technologies shares at an average price of $1.56 per share. Currently, the stock trades at $1.71 per share, having gained 5.93% year-to-date. Over the past 12 months, CPS Technologies Corporation shares dropped 7.82%.

Analyst coverage for CPS Technologies stock is currently limited.

13. MAIA Biotechnology, Inc. (NYSEAMERICAN:MAIA)

Market Capitalization: $48.3 million

MAIA Biotechnology is an immuno-oncology company specializing in targeted therapies aimed at enhancing the treatment of cancer. Its primary candidate, THIO, is a novel drug in clinical trials designed to target telomeres in cancer cells, specifically for non-small cell lung cancer (NSCLC) patients with telomerase-positive tumors.

Recently, the company announced that preclinical data for its lead cancer treatment, the THIO dimer, was published in a scientific journal. The study showed that THIO and its dimer form effectively block a key enzyme (GSTP1) involved in cancer progression and drug resistance, suggesting the dimer could improve chemotherapy effectiveness by reducing resistance.

This month, two insiders acquired approximately $1.19 million worth of MAIA shares at an average price of $1.50 per share. Year-to-date, the stock is down 15.66%, trading at $1.67 per share. Over the past 12 months, MAIA shares lost 34.51%.

According to TipRanks, one Wall Street analyst rates MAIA stock as a “Moderate Buy” with a price target of $14.00. The price target suggests a potential upside of 738.32% from the latest price.

12. GrowGeneration Corp. (NASDAQ:GRWG)

Market Capitalization: $76.11 million

GrowGeneration owns and operates retail hydroponic and organic gardening stores across the U.S. It sells a variety of cultivation products, including nutrients, lighting, and growing media, through physical stores and an online platform. The company also provides storage solutions and services such as site surveys, floor plan designs, and installations, serving markets like agriculture, retail, and hospitality.

For the full year of 2024, GrowGeneration reported net sales of $37.0 million, compared to $225.9 million in 2023. Gross profit was $43.7 million, compared to $61.3 million in 2023. Selling, general, and administrative expenses amounted to $29.2 million, which compares to $29.8 million for 2023, a decrease of 1.9%. GAAP net loss was $49.5 million for the year, compared to $46.5 million in 2023.

In March, two insiders, including the CEO, bought around $201,753 worth of GrowGeneration shares at an average price of $1.20 per share. The stock now trades at $1.28 per share, down 24.26% year-to-date, and 49.61% over the past 12 months.

Based on the estimates of two Wall Street analysts, GrowGeneration stock is rated a “Moderate Buy,” according to TipRanks. The average price target of $2.63 suggests a 105.47% upside from the last price of $1.28.

11. SmartRent, Inc. (NYSE:SMRT)

Market Capitalization: $231.24 million

SmartRent is a real estate technology company that offers software and hardware solutions for property owners, managers, homebuilders, and residents. Their products include smart building systems, access control, asset monitoring, and self-guided tours, all designed to enhance property management and resident experience. It is based in Scottsdale, Arizona.

We recently shared a bull case theory on SmartRent. In summary, the thesis argues that despite SmartRent stock hitting all-time lows, it offers a strong investment opportunity as most of its market value is backed by cash. The company, which focuses on subscription software for multifamily buildings, generates $75 million in annual subscription sales and $50 million in gross profits, yet trades at a very low valuation. An activist investor’s involvement and the company’s solid financial position provide strong downside protection, making the stock a compelling risk/reward investment with the potential for significant upside.

This month, three insiders, including the CEO, and CFO, acquired approximately $212,349 worth of SmartRent shares at a price of $1.19 per share. Currently, the stock trades at $1.20 per share, having dropped 31.43% since the beginning of the year, and 55.89% over the past 12 months.

Four analysts have rated SmartRent stock as a “Hold” with a price target of $1.87, suggesting a potential upside of 55.83%.

10. Alzamend Neuro, Inc. (NASDAQ:ALZN)

Market Capitalization: $6.73 million

Alzamend Neuro, a clinical-stage biopharmaceutical company, ranks 10^th among the 15 cheapest stocks insiders are buying this month. The Atlanta, Georgia-headquartered company focuses on developing treatments for neurodegenerative and psychiatric disorders. Its pipeline includes AL001, a combination therapy for Alzheimer’s and other mental health conditions, and ALZN002, a cell-based therapeutic vaccine for Alzheimer’s. The company partners with Massachusetts General Hospital for AL001’s Phase II clinical trial.

The company recently announced plans to begin a Phase II clinical study of AL001 for the treatment of patients with Major Depressive Disorder (MDD) in the fourth quarter of 2025. This follows the successful completion of a head coil by Tesla Dynamic Coils BV, a crucial component for the trial. In partnership with Massachusetts General Hospital as its contract research organization, Alzamend aims to investigate the unique properties of AL001 and its effects on lithium delivery in the brain compared to existing lithium salts.

This month, two insiders, including the CFO, purchased around $14,621 worth of Alzamend Neuro shares at an average price of $0.90 per share. Since the beginning of the year, Alzamend shares have declined 12.07%, trading at $1.02. Over the past 12 months, Alzamend lost 89.90%.

StockAnalysis reports that one analyst has rated Alzamend Neuro stock as a “Strong Buy” with a price target of $20.00.

9. Fathom Holdings Inc. (NASDAQ:FTHM)

Market Capitalization: $27.07 million

Fathom Holdings is a real estate services platform that integrates residential brokerage, mortgage, title, and insurance services in the U.S. The Cary, North Carolina-based company operates in three segments: Real Estate Brokerage, Mortgage, and Technology, offering tools and services through its FathomRealty.com website and technology platform, intelliAgent. Fathom’s brands include Fathom Realty, Dagley Insurance, Encompass Lending, and Verus Title.

Fathom completed approximately 37,000 real estate transactions in 2024, marking a 2.2% decline compared to the previous year. Total revenue for 2024 decreased by 3%, totaling $335 million, down from $345 million in 2023. The GAAP net loss for 2024 was $21.6 million, or $1.07 per share, improving from a loss of $24.0 million, or $1.47 per share, in 2023, mainly due to cost-saving initiatives. The Adjusted EBITDA loss for 2024 was $5.7 million, compared to a loss of $4.1 million in 2023, driven by the 3% revenue reduction. Cash and cash equivalents as of December 31, 2024, decreased to $7.1 million from $7.4 million at the end of 2023.

In March, two insiders bought nearly $600,000 worth of Fathom Holdings shares at an average price of $0.72 per share. Currently, the stock trades at $1.00 per share, having dropped 34.64% year-to-date and 50% over the past 12 months.

According to MarketBeat, four analysts have given an average “Buy” rating to Fathom stock with a price target of $4.25. The average price target suggests a potential upside of 325% from the latest price.

8. VerifyMe, Inc. (NASDAQ:VRME)

Market Capitalization: $9.91 million

VerifyMe provides brand protection and precision logistics solutions, focusing on anti-counterfeit protection and specialized logistics for time and temperature-sensitive products. The Lake Mary, Florida-based company operates in two segments: Precision Logistics, offering analytics for perishable products, and Authentication, which connects brands with consumers and protects against counterfeiting. VerifyMe also offers services like product traceability and customer engagement through various software tools.

For the fourth quarter of 2024, the company disclosed revenue of $7.7 million, compared to $8.7 million in the same period of 2023. Gross profit amounted to $2.4 million, versus $2.9 million in the same quarter of the prior year. Net loss was $500,000, compared to net income of less than $100,000 in the corresponding quarter of 2023. Adjusted EBITDA was $500,000, compared to $1.1 million in the fourth quarter of 2023.

In March, two insiders, including the CEO and president, bought approximately $86,205 worth of VerifyMe shares at a price of $0.70 per share. The stock now trades at $0.80 per share, down 41.01% year-to-date and 42.69% over the past 12 months.

Two Wall Street analysts have rated VerifyMe stock as a “Moderate Buy” with a price target of $1.25 per share, reports TipRanks. The average price target suggests a 55.80% potential upside from the current price.

7. Tenaya Therapeutics, Inc. (NASDAQ:TNYA)

Market Capitalization: $113.81 million

Next on this list of 15 cheapest stocks insiders are buying in March is Tenaya Therapeutics. The South San Francisco, California-based company discovers, develops, and delivers therapies for heart disease in the United States.

For the full year 2024, Tenaya Therapeutics reported a net loss of $111.1 million, or $1.31 per share, compared to a net loss of $124.08 million in 2023. Research and development expenses were $86.7 million, down from $98.0 million the previous year.

As of December 31, 2024, the company held $61.4 million in cash, cash equivalents, and marketable securities, a decrease from $104.6 million as of December 31, 2023. With an additional estimated $48.9 million in net proceeds from the March 2025 public offering, Tenaya expects its current funds will be sufficient to support operations through mid-2026.

Recently, the company announced positive preclinical results for its gene therapy candidate, TN-201, which targets MYBPC3-associated hypertrophic cardiomyopathy (HCM), a common genetic cause of heart disease. TN-201 is designed to deliver a working MYBPC3 gene to heart cells, increasing the MyBP-C protein to help treat or even reverse the disease. Preclinical data showed that TN-201 improved heart function and reversed key symptoms of HCM, such as thickening of the heart’s left ventricle. The therapy is now being tested in a clinical trial, MyPEAK-1, at higher doses.

This month, two insiders bought nearly $50 million worth of Tenaya Therapeutics shares at an average price of $0.70 per share. Currently, the stock trades at $0.70, having declined 51.05% year-to-date and 85.60% over the past 12 months.

According to TipRanks, seven analysts have given an average “Buy” rating to Tenaya Therapeutics stock with a price target of $6.25 per share. The average price target suggests a potential upside of 792.86% from the latest price.

Additionally, Tenaya is one of the 13 penny stocks with insider buying in 2024.

6. Lyell Immunopharma, Inc. (NASDAQ:LYEL)

Market Capitalization: $165.09 million

Lyell Immunopharma is a clinical-stage cell therapy company focused on developing CAR T-cell therapies for hematologic malignancies and solid tumors. The company is advancing therapies using innovative approaches to improve T-cell resistance to exhaustion and enhance antitumor activity. Lyell is developing the IMPT-314 dual-targeting CAR T-cell product for aggressive relapsed/refractory lymphoma and has a preclinical solid tumors program.

The company reported a net loss of $191.9 million for the fourth quarter and $343.0 million for the year ended December 31, 2024, compared to a net loss of $52.9 million for the fourth quarter and $234.6 million for the year in 2023. Research and development (R&D) expenses were $48.7 million and $171.6 million for the fourth quarter and full year of 2024, respectively, compared to $47.0 million and $182.9 million for the same periods in 2023. Cash, cash equivalents and marketable securities as of December 31, 2024 were $383.5 million compared to $562.7 million as of December 31, 2023. Lyell believes that its cash, cash equivalents and marketable securities balances will be sufficient to meet working capital and capital expenditure needs into 2027.

In March, two insiders, including the CFO, purchased approximately $312,752 worth of Lyell Immunopharma shares at an average price of $0.59 per share. The stock now trades at $0.56 per share, having dropped 12.62% year-to-date and 70.87% over the past 12 months.

StockAnalysis reports that two analysts have rated Lyell Immunopharma stock as “Sell” with a price target of $1.0. The average price target suggests a 78.89% upside from the latest price.

5. AEye, Inc. (NASDAQ:LIDR)

Market Capitalization: $12.86 million

AEye ranks fifth among the 15 cheapest stocks insiders are buying in March. The Pleasanton, California-headquartered company designs and provides lidar systems for vehicle autonomy, advanced driver-assistance systems, and robotic vision applications in the U.S. and Europe. Its main product is the 4Sight Intelligent Sensing Platform, a solid-state lidar sensor for safety-critical applications in automotive and non-automotive markets.

For the full year 2024, AEye reported revenue of $202,000, which compares to revenue of $1.46 million in 2023. Net loss amounted to $35.46 million, compared to a net loss of $87.13 million in the previous year.

“AEye just closed out a transformational year marked by significant milestones including a new product launch, extended financial runway, increased engagement with OEM customers, and expansion into new markets,” stated Matt Fisch, AEye CEO. “Apollo has officially launched in the U.S. and is currently being tested in the field by customers interested in its differentiated capabilities for a range of applications where high visibility is mission critical. Our strategic partnerships in China are also contributing to increased exposure to prospective customers, thanks to our partners’ well-established networks and supply chains in the region.”

In March, three insiders, including the CEO, bought around $47,794 worth of AEye shares at an average price of $0.57 per share. Currently, the stock trades at $0.69 per share, down 45.82% year-to-date and 60.23% over the past 12 months.

Analyst coverage for AEye is currently limited.

4. EON Resources Inc. (NYSEAMERICAN:EONR)

Market Capitalization: $7.54 million

EON Resources Inc. is an independent oil and natural gas company focused on the acquisition, development, and production of properties in the Permian Basin. The Houston, Texas-based company holds a 100% working interest in 343 wells and 207 injection wells across 13,700 acres.

In recent developments, EON Resources signed a non-binding Letter of Intent (LOI) with Enstream Capital Management for a $52.8 million revenue-sharing and volumetric funding arrangement (VMA), expected to close by June 2025. The VMA capital will be used to settle the Seller consideration, pay off a reserve-based loan, and fund workovers on 45 wells. This agreement improves cash flow by $250,000 per month, reduces debt by $40 million, avoids stock dilution, and shields the company from oil price risk, all while retaining the option to buy back the ORRI at a minimal cost.

This month, two insiders, including the CFO, acquired approximately $87,419 worth of EON Resources shares at an average price of $0.53 per share. Year-to-date, the stock is down 28.67%, trading at $0.58 per share. Over the past 12 months, its shares have declined 78.50%.

According to StockAnalysis, one analyst rates EON Resources stock as a “Strong Buy” with a 12-month stock price target of $4.50.

3. Earth Science Tech, Inc. (OTCPK:ETST)

Market Capitalization: $36.61 million

Earth Science Tech, Inc. is a health and wellness company based in Miami, Florida. It operates Peaks, a telemedicine referral site for men and women, and a pharmacy under the RxCompound name. The company was founded in 2010 and rebranded from Ultimate Novelty Sports, Inc. to its current name in 2014.

In March, three insiders, including the COO, and CTO, purchased $22,535 worth of Earth Science shares at an average price of $0.14 per share. Currently, the stock trades at $0.12, having declined 5.31% since the beginning of the year. However, over the past 12 months, Earth Science returned 75.86% to its investors.

Analyst coverage for Earth Science is currently limited.

2. Liberty Star Uranium & Metals Corp. (OTCQB:LBSR)

Market Capitalization: $6.03 million

Liberty Star Uranium & Metals is a mineral resource company focused on acquiring and exploring mineral properties in Arizona. The Tucson, Arizona-based company primarily explores for copper, gold, silver, uranium, and other metals, with its main property being the Hay Mountain Property, which covers over 14,000 acres.

Recently, the company described 2024 as a breakthrough year for its exploration efforts, with significant discoveries at its Red Rock Canyon Gold Project and Hay Mountain Project in southeast Arizona. The company completed its first-ever drilling at Hay Mountain, confirming the potential for a large-scale porphyry copper-gold system and made bonanza-grade gold discoveries at Red Rock Canyon. Liberty Star is seeking a joint venture partnership to advance both projects, which are located in a regionally significant mineral system extending from Arizona into northern Mexico.

This month, four insiders, including the CFO, bought around $326,402 worth of Liberty Star Uranium & Metals shares at an average price of $0.09 per share. The stock gained 2.05% since the beginning of the year and now trades at $0.11 per share. Over the past 12 months, its shares have lost 72.62%.

The analyst coverage on Liberty Star Uranium & Metals is currently limited.

1. Zomedica Corp. (OTCQB:ZOMDF)

Market Capitalization: $66.64 million

Zomedica, a veterinary health company, ranks first among the 15 cheapest stocks insiders are buying in March. The Ann Arbor, Michigan-headquartered company develops diagnostic and therapeutic products for companion animals. Its offerings include diagnostic platforms like TRUFORMA and TRUVIEW, as well as therapeutic products such as PulseVet and Assisi Loop devices for pain and inflammation treatment. The company also collaborates with Celsee, Inc. and Seraph Biosciences, Inc. to develop advanced diagnostic and pathogen detection solutions.

For the full year 2024, Zomedica disclosed revenue of $27.3 million, compared to $25.2 million for 2023. Operating expenses were $70.1 million, including a full year of expenses related to Qorvo Biotechnologies, compared to $60.6 million the previous year. Research and development expenses amounted to $7.3 million, compared to $5.8 million for 2023. Net loss was $47.0 million, which compares to a net loss of $34.5 million in 2023.

In March, eight insiders, including the CEO, COO, and CFO, acquired approximately $279,286 worth of Zomedica shares at an average price of $0.07 per share. Currently, the stock trades at $0.068, having declined 43.33% year-to-date and 50.72% over the past 12 months.

According to TipRanks, one Wall Street analyst has rated Zomedica stock as a “Moderate Buy” with a price target of $0.25 per share. The average price target suggests a potential upside of 284.62% from the latest price.

Overall, ZOMDF is first among the 15 cheapest stocks insiders are buying in March. While we acknowledge the potential of ZOMDF our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns, and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than ZOMDF but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock.

READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires.

Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below.